GSK May Launch Boostrix Vaccine Ahead Of June CDC Recommendation
This article was originally published in The Pink Sheet Daily
Executive Summary
The tetanus, diphtheria and pertussis vaccine clears FDA for patients ages 10 through 18. The vaccine approval follows the advisory committee's 13-0 unanimous recommendation in favor of use in that population, as well as its recommendation for a postmarketing trial.
You may also be interested in...
Boostrix And Adacel Get Universal Recommendation For 11-12 Year-Olds
CDC’s Advisory Committee on Immunization Practices also recommends catch-up Tdap vaccination for adolescents who have already received a Td booster. ACIP further recommends concomitant administration of Tdap with Sanofi-Aventis’ meningococcal conjugate vaccine Menactra.
Boostrix And Adacel Get Universal Recommendation For 11-12 Year-Olds
CDC’s Advisory Committee on Immunization Practices also recommends catch-up Tdap vaccination for adolescents who have already received a Td booster. ACIP further recommends concomitant administration of Tdap with Sanofi-Aventis’ meningococcal conjugate vaccine Menactra.
Sanofi-Aventis' Adacel Launch Plans Await CDC Recommendations
FDA clears the tetanus, diphtheria, pertussis booster vaccine for individuals ages 11-64. Phase IV commitments include a concomitant use study with Sanofi's meningococcal vaccine Menactra.